Objectives: To evaluate 1-year outcome using the ACURATE neo (Symetis S.A., a Boston Scientific Company, Ecublens, Switzerland) according to the updated Valve Academic Research Consortium (VARC-2) with emphasis on the composite endpoints "clinical efficacy after 30 days" and "time-related valve safety". Background: Initial reports on the clinical performance of patients treated with the ACURATE neo are promising; however, information regarding one-year outcome is scarce, especially with regard to the composite endpoints proposed by the VARC-2. Methods: One hundred and fifty one consecutive patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) with the ACURATE neo for severe aortic valve stenosis were enrolled. Data were prospectively collected and event rates during follow-up were calculated as the Kaplan-Meier estimates. Results: Mean age was 81.1 ± 5.9 years and 49.7% (75/151) were female with a median logistic EuroScore of 13.8% [8.2-20.5]. Device success was achieved in 88.1% (133/151) and procedure related mortality was 0.7% (1/151). At one-year, all-cause mortality was 3.3% (5/151), while permanent pacemaker implantation occurred in 12.7% (19/151) of patients. The "clinical efficacy after 30 days" was observed in 24.8% (37/151), where the main contributor was symptom worsening in 14.8% (22/151) of cases. "Time-related valve safety" occurred in 22.0% (33/151) with structural valve deterioration as main contributor in 10.7% (16/151) of cases. Conclusions: Using the ACURATE neo, we found a favorable safety profile with low all-cause mortality at 1 year. The reported VARC-2 defined composite endpoints at 1 year reveal low rates of "clinical efficacy after 30 days" and "time-related valve safety". K E Y W O R D S ACURATE neo, aortic valve stenosis, outcome, transfemoral transcatheter aortic valve replacement, VARC-2
| INTRODUCTION
Since the first procedures performed in 2002, transcatheter aortic valve replacement (TAVR) has rapidly evolved from a treatment for inoperable patients to a standard therapeutic strategy for high-risk patients with ongoing extension toward intermediate and low-risk populations. 1, 2 With advances in so called "next" generation transcatheter heart valves (THVs), increasing operator experience and development of low-profile delivery systems, procedural outcomes have improved considerably.
Indeed, one-year mortality rates have been reduced from 24% with early generation devices 3 to 12% with next generation devices. 1 Various next generation THVs are currently available, among them the self-expanding ACURATE neo (Symetis S.A., a Boston Scientific Company, Ecublens, Switzerland). Large-scale data on this novel THV are scarce. So far, initial data from the SAVI TF 4, 5 and the MORENA multicentre registry 4,5 appear promising. Both registries have shown good shortterm results and a 30-day mortality rate ranging from 1.4 to 2.3%. Of special note for a self-expanding device, the rate of new permanent pacemaker implantation (PPI) was very low, ranging between 8.3 and 10.2%. 6 As far as longer-term outcomes are concerned, one-year clinical data from the SAVI TF registry reported a very low all-cause mortality rate of 8.4%. 7 Apart from these, however, one-year outcome data for the ACURATE neo is scarce, especially with regard to composite endpoints at 1 year as proposed by the updated criteria of the Valvular Academic Research Consortium (VARC-2). 8 These well-defined endpoints are important for the comparability of data and enable a standardized assessment of outcome. Therefore, this study provides one-year outcome according to the VARC-2 criteria with the novel self-expanding ACURATE neo from a single center.
| METHODS

| Patient population
Between January 2014 and October 2016, all patients undergoing TAVR using the ACURATE neo for severe symptomatic stenosis of the native aortic valve at our institution were included (n = 151). All cases were discussed in the multidisciplinary heart team and consensus was achieved regarding the therapeutic strategy. All patients provided written informed consent prior to the procedure. TAVR was performed in a hybrid operating suite under general anesthesia or conscious sedation.
| Multislice computed tomography data analysis and prosthesis size selection
Multislice computed tomography (MSCT) was performed as part of the standard pre-procedural screening protocol. Aortic annulus measurements were assessed in multiple plane reconstructions according to the guidelines of the Society of Cardiovascular Computed Tomography 9 and as previously described. 10 Dedicated FDA-approved software (OsiriX MD 3.9.4, Pixmeo, Switzerland) was employed.
The technical features of the ACURATE neo have been previously described. 11 The ACURATE neo is currently available in three sizessmall, medium and large-covering a range from 21 to 27 mm annulus diameter. The final decision on prosthesis size was left at the discretion of the physicians performing the procedure and was based on both, MSCT measurements and individual anatomical features.
| Echocardiography and follow-up
All data up to 1 year were prospectively collected with routine ambulatory visits at the outpatients' clinic, telephone call, information from the treating physician, or other hospital documentation. Transthoracic echocardiography was performed before TAVR, at discharge, at 30 days and at 1-year in the outpatients' clinic or by the treating cardiologist. Left ventricular ejection fraction, mean transvalvular gradient and degree of paravalvular regurgitation were assessed.
During follow-up, echocardiography data are reported for patients with complete echocardiography and known mortality status at 30 days (n = 142/151).
| Definition of endpoints
All clinical and procedural endpoints in-hospital and during follow-up were categorized according to the VARC-2 criteria. 12 At 1 year after TAVR, the occurrence of two composite endpoints was recorded: "Time-related valve safety" is composed of structural valve deterioration (mean aortic valve gradient ≥20 mmHg, effective orifice area ≤ 0.9-1.1 cm 2 and/or moderate or severe PVL), prosthetic valve endocarditis or thrombosis, stroke and bleeding. "Clinical efficacy after 30 days" consists of all-cause mortality, disabling or non-disabling stroke, hospitalizations for valve-related symptoms or worsening of congestive heart failure (CHF), symptom worsening with NYHA class III or IV and valve-related dysfunction as described above.
Additionally, two composite endpoints at 1 year after TAVR, "death or readmission for CHF" and "death or stroke" were analyzed as these constitute composite endpoints often reported in recent trials and registries. 3, 13 
| Statistical analysis
| RESULTS
| Patient characteristics, procedural and inhospital outcome
In total, 151 patients were included in the analysis. Mean age was 81.1 ± 15.9 years and 49.7% were female. Median EuroScore I was 13.8% [8.2-20.5] . Table 1 displays the clinical and MSCT characteristics of the study population, showing moderate to severe valve calcification in 74.2% (112/151) of patients.
Procedural and in-hospital outcome is depicted in Table 2 . The majority of procedures were performed under general anesthesia (94.0%) and the small, medium and large prosthesis sizes were used in 33.1, 36.4, and 30.5%, respectively. Median procedural time was 66.6 ± 22.0 min and 146.2 ± 51.9 mL of contrast was used. VARC-2 defined device success was achieved in 88.1% with paravalvular leakage II+ being the main contributor in 7.9% of cases.
One patient died in-hospital during emergency surgery for annular rupture, which occurred after implantation of a second prosthesis because of residual severe PVL. Rates of life-threatening bleeding, major vascular complications and all strokes (major or minor) were 5.3, 13.9, and 1.3%, respectively. New PPI rate in pacemaker naive patients was 10.2% (14/137) and 9.3% (14/151) considering the entire study population. Median stay on intensive care unit and inhospital after the procedure was 1 [1-2] days and 5 [4] [5] [6] days, respectively.
| 30-day and one-year outcome after TAVR
Clinical follow-up at 1 year was complete for 97.4% of the patients.
The Kaplan-Meier estimates of event rates at 30 days and 1 year are displayed in Table 3 . All-cause mortality at 30 days was 0.7% and increased to 3.3% at 1 year. Cardiac mortality at 1 year was 1.3%. Rates of stroke (major or minor) and life-threatening bleeding increased by 2.1 to 3.4% and by 3.4 to 8.7% from 30 days to 1 year, respectively.
The composite of death and stroke occurred in 6.7% at 1 year ( Figure 1A ). Percutaneous coronary intervention at 1 year was required in 6.8% of patients; in three cases for acute myocardial infarction, and the rest for elective coronary intervention for stable symptomatic coronary artery disease. Hospitalization rates for worsening of CHF were 2.7% at 30 days and increased to 7.4% at 1 year. The cumulative incidence of death and hospitalization for CHF was 9.3% ( Figure 1B) . PPI rates in patients without prior pacemaker were 11.7% and 14.0%, at 30 days and 1 year, respectively. The combined early safety endpoint at 30 days occurred in 17.9%.
| Evolution of NYHA class
Changes in NYHA functional class category before TAVR and during follow-up is visualized in Figure 2 and shows a considerable symptomatic benefit: at baseline 59% of patients were in NYHA class III/IV, while 92.7% at 30 days and 86.7% at 1 year after TAVR reported a NYHA functional class II or less. At 1 year, NYHA class was not available for 5.9% of patients, either due to death (3.3%) or was missing (2.6%). From baseline to 1 year, symptom improvement of at least one functional class was observed in 70.9% of patients.
| Echocardiographic follow-up
Echocardiographic follow-up for patients discharged alive, 30 days and 1 year was available for 100, 94.0, and 85.6%, respectively.
Mean transvalvular gradients at discharge were 8.5 ± 4.0 mmHg and remained low at 30 days (7.8 ± 3.3 mmHg) and 1 year (6.9 ± 3.0 mmHg; p < 0.001). Both these patients had small aortic annuli and were treated with a "small" prosthesis. As underlying reason to this finding, valve thrombosis was ruled out by transesophageal echocardiography in one patient, while the other was already on oral anticoagulation therapy with a vitamin-K antagonist for atrial fibrillation and therefore thrombus formation an unlikely cause.
| VARC-2 defined composite endpoints at 1 year
The "clinical efficacy after 30 days" endpoint was observed in 24.8% of the patients after 1 year. The individual contributors to this composite endpoint are depicted in Figure 4A , with worsening of NYHA functional class being the main reason in 14.8% of cases.
The composite endpoint "time-related valve safety" occurred in 22 .0%. Figure 4B shows the individual contributors to this endpoint, with structural valve deterioration having a cumulative incidence of 10.7% at 12 months.
| DISCUSSION
In this single center observational analysis of a contemporary TAVR population treated with the novel self-expanding ACURATE neo, we found excellent clinical outcome with a notably low 1-year mortality.
Furthermore, for the first time for this THV, VARC-2 defined composite endpoints at 1 year are reported, namely "clinical efficacy after 30 days" and "time-related valve safety".
| One-year outcome after TAVR with the ACURATE neo
The initial experience from the transfemoral ACURATE neo CEapproval cohort showed all-cause mortality and stroke rates at 1 year of 22.5 and 6.7%, respectively. 14 However, it must be considered that this was a high-risk, multimorbid population with a mean logistic Euro-Score of 26.5%. When considering a more contemporary, in parts intermediate risk-population, such as the population treated in the SAVI-TF registry, all-cause mortality and stroke rate were much lower with 9 and 3.6%, 7 respectively. This is in line with other large-scale reports for similar risk populations treated with other contemporary THVs, such as the balloon-expandable SAPIEN 3 valve. 13, 15 In a recent single-center study, an even lower one-year mortality was achieved with the ACURATE neo, namely of 5.2%. 16 This is comparable with the low mortality and stroke rate found in the present population of 3.3 and 3.4%, respectively, pointing toward excellent clinical results. These results have to be put into perspective, for example it will be interesting to see, whether a further improvement of results can be achieved by changing the anesthesiological strategy.
In our analysis, conducted between 2014 and 2016 general anesthesia was applied in the vast majority of cases. Currently, however, we are observing a transition toward conscious sedation as the preferred technique with excellent, even superior results compared to general anesthesia. 17 Low rates of PPI have been reported with the ACURATE neo, ranging from 2.3 to 9.9% at 30 days 18, 19 and increasing to 11.5% at of complete right bundle branch block at admission, which is one of the main known risk factors for PPI. 22 In this population, it was 8.6%.
| VARC-2 composite endpoints with the ACURATE neo
The standardized definitions proposed by the updated VARC-2 set a uniform framework for evaluation and comparison of clinical outcomes after TAVR. Although the adoption of VARC-criteria has increased over time, 23, 24 the application is often limited to assessment of in-hospital outcomes, while the report of important composite endpoints remains scarce, 5, [25] [26] [27] and potentially impedes direct comparisons. The endpoint "device success" is an important measure of shortterm procedural success and THV function. 12 For the ACURATE neo device, success rates range from 89 to 98.7%. 4, 5, 14 In the present analysis, we found rates of 88.1%, mainly driven by PVL II+ in 7.9%, which seems slightly higher compared to previously reported rates of 5% for this THV. 4, 18 PVL is difficult to quantify as there are different modalities for the evaluation, ranging from angiography, echocardiography, or hemodynamic assessment for example, the aortic regurgitation index. 28, 29 Furthermore, timing of assessment plays an important role.
Accordingly, in this analysis, we observed a different rate of PVL when considering angiography and echocardiography at discharge, namely Need for post-dilatation correlates with valve calcification, especially for self-expanding devices. 30 In the present analysis, more than two-thirds of patients had moderate to severely calcified valves and, in these patients, post-dilatation was performed significantly more often compared to patients without moderate to severe calcification (66.1% (74/112) vs. 38.5% (15/39); p = 0.003). This may at least partly account for the increased need of post-dilatation, as well as the slightly higher rates of PVL II+ observed in this study. Nevertheless, due to the negative prognostic impact of residual PVL, efforts must be made to further reduce PVL rates. In this regard, a next iteration of the ACURATE neo, the ACURATE neo 2.0, featuring an additional sealing skirt to reduce PVL is currently in CE mark studies.
The "early safety composite endpoint at 30 days" has been Data on "clinical efficacy after 30 days" and "time-related valve safety" are scarce in general. Specifically, for the ACURATE neo, to the best of our knowledge, there are no reports in the present literature. We found a relatively high incidence of these composite 
| Limitations
This single center experience is limited by the relatively small sample size, observational nature and lack of core lab analysis of echocardiographic data.
| CONCLUSIONS
In this single-center analysis using the novel ACURATE neo, we found 
